Paxlovid does not reduce symptoms, definitive Pfizer trial finds.
Pfizer finally published its study of Paxlovid’s effects on symptoms for standard-risk and high-risk vaccinated patients with Covid-19. No difference in symptoms. The upshot of the trial, known as EPIC-SR and published in the New England Journal of Medicine